Analbuminemia is a very rare recessive disorder in which subjects have little or no circulating albumin, although albumin is normally the most abundant plasma protein and has many functions. Analbuminemla is caused by Abbreviations: HSA, human serum albumin; SSCP, single-strand conformation polymorphism.
a variety of mutations in the albumin gene and is exhibited only by subjects homozygous for the defect. Previously the mutation had been identified at the molecular level in only two human cases; in one case it resulted from an exon-splicing defect, and in the other case it was caused by a nucleotide insertion that caused a frameshift and premature stop codon. In this investigation we identified the mutations in three unrelated subjects from different countries. In each instance a single-nucleotide mutation produced a stop codon, but the mutations occurred at three different sites: (i) in an Italian male a C -> T transition at nt 2368 in the genomic sequence of albumin, (u) a C -. T transition at nt 4446 for an American female, and (iU) a G -+ A transition at nt 7708 in a Canadian male. The size of the albumin fragment that might have been produced for the three cases varied from 31to 213-amino acid residues, but no evidence for a circulating albumin fragment was obtained. The paradox is that analbuminea is extremely rare (frequency < 1 x 10'); yet the virtual absence of albumin is tolerable despite its multiple functions. Analbuminemia is an extremely rare, relatively benign condition in which subjects produce little or no albumin despite the fact that this protein is normally the most abundant serum protein and has many functions (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Analbuminemia is readily detected by serum electrophoresis, a common clinical analysis, yet only -30 cases have been recorded, and the frequency is probably <1 x 106 (12). Homozygous individuals with analbuminemia have only 1/100th to 1/1000th the normal serum concentration of albumin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , but heterozygous family members shown to carry the mutant gene have nearly normal levels (3.5-4.5 g/dl) (12). One chieffunction of albumin is to bind and transport many metals, hormones, ligands, and therapeutic drugs, as well as metabolites such as bilirubin (1, 13) . Another function is to maintain blood volume and colloid osmotic pressure; hence, albumin is frequently administered in shock or trauma. In fact, -5 x 106 units of albumin (12.5 g/unit) are used annually in the United States. Except for associated hyperlipidemia, minor edema, and mild fatigability, analbuminemic individuals suffer few, if any, adverse symptoms and may live a full life-span. The paradox is the rarity of analbuminemia despite the fact that this condition is tolerable.
Human serum albumin (HSA) consists of a single polypeptide chain of 585-amino acid residues containing 17 disulfide bonds; the chain is folded into a heart-shaped mole-cule consisting of three homologous domains, each of which has two subdomains (1, 13) . Albumin is encoded on chromosome 4 by a single gene for which the genomic sequence has been reported (14). The HSA-encoding gene contains 16,961 nt and is split into 15 exons by 14 introns (14) .
More than 50 different mutations in the HSA-encoding gene that produce genetic variants (alloalbumins) have been identified (15) (16) (17) (18) (19) , as well as two mutations that cause analbuminemia (11, 12) . Most alloalbumins have a singleamino acid substitution, resulting from a point mutation (15) (16) (17) (18) (19) ; a few alloalbumins have a truncated and altered carboxyl terminus (15, 16) . Alloalbuminemia is rare, having a cumulative frequency in most populations of =1:3000; the albumin level is generally normal, and most alloalbumins are expressed at about half the total albumin content because the condition is usually heterozygous. In comparison, the gene defect in analbuminemia had been reported in only two human cases. In an American Indian girl the mutation resulted from an exon-splicing defect (11), but in an Italian family (Roma) the mutation was caused by insertion of a single nucleotide that caused a frameshift and premature stop codon (12).
In a continued study of this disorder we have identified the gene mutation in three additional analbuminemia cases, each of which has been followed for two or more decades. The three subjects are unrelated; one is an American woman (2), the second is a Canadian male (8, 9) , and the third is an Italian male (7). All three cases result from a single-nucleotide mutation that produces a stop codon, but the mutations are at different sites. The putative aborted product ofthe albumin gene would have varied in size from only 31to 213-amino acid residues, but no such product could be identified.
MATERIALS AND METHODS
Subjects. Blood as a source of DNA was obtained with informed consent from three unrelated individuals living in different countries. One person, an American woman in her seventh decade, had in the 1950s been the subject of extensive clinical and metabolic studies reported by Gordon et al.
(2), who designated her G.M. Another was a Canadian male who in 1975 had been reported to have analbuminemia as a neonate (8) and was followed subsequently (9); to preserve confidentiality, he is designated here as Canadian. The third is an Italian male now in his sixth decade who is designated here by his place of residence, Codogno; clinical studies of this case were reported by Di Guardo et al. (7) . In all three cases only DNA could be studied, for G.M. was regularly infused with albumin and the other two subjects had negligible circulating albumin.
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Biochemistry: Watkins et al. DNA Preparation and PCR Amplification. High-molecularweight DNA was prepared by proteinase K treatment and phenol extraction of leukocytes from fresh blood specimens (12). Primer sets (designated AO1A and A02A, etc.) that encompassed the 14 coding exons of the HSA-encoding gene and their intron-exon junctions were synthesized by the DNA-synthesis facility of Indiana University (12). These primer sets were used to PCR-amplify regions of the HSA gene ranging from 288 to 464 bp in length (12). PCR amplification (20) was done in a 100-,ul reaction volume similar to the manufacturer's directions for "hotstart" PCR with Am-pliWax PCR Gems (Perkin-Elmer/Cetus) [10 mM Tris HCl, pH 8.3/50 mM KCI/1.0-2.0 mM MgCl2/0.1 1LM of each primer/200 ;LM of each deoxynucleotide/1 ug of genomic DNA/and 2.5 units of AmpliTaq DNA polymerase (Perkin-Elmer/Cetus)]. The reactions were amplified with a Perkin-Elmer/Cetus DNA thermal cycler for 40 cycles by using the following protocol: 1 min at 940C, 2 min at 500C, and 3 min at 720C with a 5-sec increase in extension time for each successive polymerization step.
Heteroduplex and Single-Strand Conformation Polymorphism (SSCP) Analysis. For heteroduplex analysis EDTA (pH 8.0) was added to the PCR products to a final 5 mM concentration. The DNA samples were denatured and reannealed slowly to form heteroduplexes, and the products were resolved in a mutation-detection enhancement gel system (AT Biochem, Malvern, PA) (12, 21, 22) . For SSCP analysis, PCR amplification was done as described above, except that the concentration of each unlabeled nucleotide was reduced to 70 ,&M, and the reactions were supplemented with 10 ,uCi of deoxyadenosine [a-[35S]thio]triphosphate (>1000 Ci/ mmol; 1 Ci = 37 GBq; Amersham) (12, 23, 24). Samples were denatured, loaded onto a mutation-detection enhancement gel, and electrophoresed as described (12).
Subcloning and DNA Sequencing. In the case of G.M., the DNA sample was PCR-amplified with primers A07A and A08A to yield a DNA product 381 bp long (12). The PCR product was cleaved with HindIII and Hae III before insertion into pBluescript cut with HindIlI and Sma I. For the Canadian sample, a region of DNA 394 bp long was amplified with PCR primers A13A and A14A (12). The PCR product was digested with Dra I and Taq I before subcloning into pBluescript cut with Sma I and Cla I. For Codogno, a 1929-bp fragment of DNA encompassing exon 2, intron 2, and exon 3 was PCR-amplified by using primers A03A and A06A (12). The PCR product was digested with Rsa I and Bgl II, and a 379-bp fragment was cloned into pBluescript (Stratagene) that had been cut with HincII and BamHI. Ligations were done by using BRL T4 DNA ligase and salts at 15°C overnight. Transformation was done by electroporation of Escherichia coli DH5a cells (GIBCO/BRL) according to the instructions for the Bio-Rad gene pulser. Two microliters of the ligated DNA was added to 40 ,ul of the cell suspension and pulsed for 4-5 msec at 25 ,F and 2.5 kV with the pulse controller set to 200 Qi. The cells were allowed to recover in 2XYT medium [16 g of Bactotryptone (Difco)/10 g of yeast extract/5 g of NaCl per liter] for 45 min at 37°C before plating (15). Screening of recombinant plasmids and double-stranded DNA sequencing were done as described (15). Both forward and reverse strands were sequenced.
RESULTS AND DISCUSSION Identification of Gene Mutations Causing Analbuminemia.
Because of the virtual absence of albumin or albumin-like proteins in the serum of subjects with analbuminemia, it is necessary to identify the mutation at the DNA level. Four possible types of mutations could cause analbuminemia: (i)
The gene could be totally absent owing to its complete deletion; this deletion would be detectable by a method such as Southern blotting. (ii) A promoter mutation upstream of the + 1 site of transcription could lead to a very low level or complete abolition of transcription from the HSA promoter; this mutation would be difficult to establish without resorting to a liver biopsy and Northern blotting of the mRNA. (iii) A splicing mutation near the intron/exon junction or at the pyrimidine-rich branch site might lead to an altered or truncated product that is inefficiently secreted or is unstable. This mutation was observed in the case of the American Indian girl (11) and was established by molecular cloning and DNA sequencing. (iv) A point mutation in one of the exons could produce a premature termination codon (a stop or nonsense codon) that would disrupt coding and result in a poorly secreted or unstable protein product. The fourth type of mutation was identified in the albumin gene in the three unrelated subjects described here, and it involved a different nucleotide in each case.
The strategy for identifying the mutation involved the following steps: (i) preparation of high-molecular-weight DNA from a fresh blood specimen, (ii) use of paired sets of primers to PCR-amplify each of the 14 coding exons and their intron-exon junctions, (iii) heteroduplex and SSCP analysis to localize the exonic site of the mutation, (iv) subcloning and DNA sequencing of PCR-amplified products containing the mutated site. Because heteroduplex and SSCP analysis examine slightly different physical parameters, the complementary use of both methods gives a higher probability of detecting single-base substitutions and also for excluding double heterozygosity for analbuminemia (25) .
Analbuminemia in an American Woman. This patient had presented with edema; an albumin level of 0.5 g/dl was obtained by a method subject to error in the positive direction (2). Clinical and metabolic studies of this individual begun in 1952 were reported at a clinical staff conference at the National Institutes of Health in 1959 (2). Ever since, she has been followed at the National Institutes of Health and has received 75 g of albumin i.v. bimonthly; hence the intrinsic albumin level cannot be determined. The family history was negative, and siblings could not be examined at that time or since. In one metabolic study the fate of albumin given i.v. was followed (2). The albumin concentration fell slowly after it was raised by the infusion; the conclusion was that the hypoalbuminemia was the result of an inability to form albumin. Investigation of the fate of 1311-labeled HSA in this patient showed that the half-life (P1/2) of the albumin was prolonged having a value of 38.5 days compared with =16 days in normal subjects and 2.5 days in patients with hypercatabolic hypoproteinemia (2). However, in G.M. the rate was directly related to the albumin pool size and became normal when total body albumin level was brought to normal by infusion. Similar findings of an increased albumin half-life have been reported in another patient with analbuminemia described by Bennhold and Kallee (4). Although diagnosed in 1952, G.M. has been in good health and has had an active career; she is now being treated for an unrelated medical problem.
In our study of DNA from G.M., heteroduplex analysis with primers A07A and A08A (12) indicated a mutation in exon 4 or the flanking intron sequences ( Fig. 1; Table 1 ). All the other exons were examined and appeared normal. SSCP analysis did not indicate a mutation in exon 4 or any other exon examined. Exon 4 encodes His-67 through the first two nucleotides of the codon for . Sequence analysis of the PCR-amplified DNA for both the forward and reverse strands established the mutation C T at nt 4446 (Fig. 2 ).
This mutation changes the codon CGA for Arg-114 to stop codon TGA, resulting in premature termination (Fig. 2) . The putative protein product would have a length of only 113 residues; however, it was not possible to obtain evidence for Proc. Natl. Acad. Sci. USA 91 (1994) Proc. Natl. Acad. Sci. USA 91 (1994) this because the patient had been given albumin i.v. bimonthly over many years.
It is noteworthy that the codon CGA contains a CpG dinucleotide and that there is evidence that CpG dinucleotides in the genes for albumin and other blood proteins are prone to mutation (28) . The codon mutated in this case of analbuminemia is the same codon that undergoes a different mutation to produce albumin Yanomama (Arg-114 -* Gly; codon CGA --GGA); the latter is an alloalbumin present in polymorphic (>1%) frequency in an Amazonian Indian tribe (29). Furthermore, the site of the mutation in G.M. is in a region of considerable divergence in amino acid sequence of mammalian albumins (30); for example, the amino acid corresponding to position 116 in human, macaque, and rat albumins is deleted in bovine, ovine, and porcine albumins.
Analbuminemia in a Canadian Male. The earliest time in life at which analbuminemia has been demonstrated was in a Canadian infant at the age of 31 days (8). This neonate had no detectable albumin until he was infused several times with albumin or whole blood from days 32 to 42. The albumin level declined rapidly and was negligible 4 mo later. The child was not given albumin thereafter. Serial blood analyses at 1½2, 31/2, and 6Y2 yr showed an albumin level of z0.1 g/dl by the methods of radial immunodiffusion and radioimmunoassay. There was a compensatory increase in other plasma proteins, primarily the immunoglobulins. The maternal family was checked for analbuminemia, and no other cases were found. The subject is now -20 yr of age; he is in good health but has occasional slight edema (Edward J. Cormode, personal communication). Recently the serum albumin concentration was determined by affinity chromatography for a protein of 67 kDa; the value was 5.2 mg/dl or :1/1000th of normal value (A. M. Soto and C. Sonnenschein, personal communication).
Heteroduplex analysis of DNA PCR-amplified with primers A13A and A14A indicated the mutation was in exon 7; all other exons examined appeared normal. SSCP analysis was not done in this case. Sequence analysis of PCR-amplifled DNA (Fig. 3) showed that the mutation is a G --A change at nt 7708 at the intron 6/exon 7 junction. This mutation, TG/G TG/A, changes the codon for Trp-214 to a stop codon ( Table 1 and Fig. 3 ; the slash mark in the codon triplet indicates the exon 6/exon 7 junction in the mRNA). It is noteworthy that Trp-214 is normally conserved in mammalian species, probably because it is an essential feature of the major ligand-binding site 1 (13) . Also, the mutation in the analbuminemic American Indian is at nt 7706 (TAG TGG); this mutation abolishes splicing and leads to truncation at a stop codon within intron 6 just after the triplet encoding . Analbumniena in an Italian Man. Analbuminemia was reported in a 39-yr-old Italian man designated here as Codogno for the region of residence (7). Analysis by rocket electrophoresis gave a serum albumin value of 5 mg/dl. The subject did not exhibit edema and was essentially asymptomatic. Total plasma protein was 5.1 g/dl because of a compensatory increase in a-and ,3-globulins and lipoproteins. Three family members had a normal albumin level. A fresh blood specimen was obtained at age 56, at which time the subject was not well due to unrelated causes, but the albumin value was unchanged.
Heteroduplex analysis of PCR-amplified DNA for all 14 exons of Codogno gave no clue about the mutation site. However, SSCP analysis of PCR-amplified DNA with primers AO5A and A06A indicated the mutation was in exon 3 or the flanking intron sequences. Sequence analysis of the 379-bp DNA fragment obtained as previously described showed a single-base mutation, C -* T, at nt 2368 (Fig. 4 ).
This resulted in the change of the codon CAG for Gln-32 to stop codon TAG. This extremely premature termination Analbuminemias designated Codogno, G.M., and Canadian are described in text; other references are in parentheses. Numbers for exons, introns, and nucleotides are based on the genomic sequence of HSA (14). indicates an intron-exon junction before splicing occurs; / indicates an exon-exon junction after splicing has occurred. *The 214-amino acid product would result from a premature termination if intron 6 were not removed. Alternatively, exon 6 may be spliced to exon 8, skipping exon 7 and thereby causing a frameshift and premature termination. tExon H = human exon 9.
Biochemistry: Watkins et al. would have encoded an albumin fragment of only 31-amino acid residues, the shortest putative product of any cases of analbuminemia for which the mutation has been identified at the DNA level ( Table 1) .
Point Mutations to Chain-Terminating Codons Cause Analbuminemia in AB Three Caes. As described above, we have identified the gene mutation in three cases of analbuminemia, each ofwhich has been followed for two or more decades. All three cases result from a single-nucleotide mutation that produces a stop codon, but the mutation is at a different site in each instance (Table 1) . One individual (G.M.) is an American woman who was the subject of extensive clinical and metabolic studies and has received i.v. albumin bimonthly for -30 yr (2); in this case a C --T change at nt 4446 in exon 4 changes the codon for Arg-114 to a stop codon. The second case is a Canadian male now in his third decade who was diagnosed with analbuminemia as a neonate (8); he was studied clinically at intervals (9), has only once received albumin, and is in good health. In this instance a G -* A mutation at nt 7708 (the first nucleotide of exon 7) produces a stop codon after Ala-213. The third case is an Italian man now -56-yr old, whose mutation is a C -> T change at nt 2368 in exon 3, which changes the codon for Gln-32 to a stop codon.
Mechanisms of Mutation in Analbuminemna. Although the three cases of analbuminemia described here result from point mutations producing a chain-terminating codon, earlier reported cases involved different mechanisms (Table 1 ). In analbuminemia Roma the mutation was an insertion of a single adenine in the normal AAAA sequence ofnt 9156-9159 in exon 8 (12). This insertion produced a frameshift followed by a stop codon and termination seven codons downstream. Analbuminemia (Codogno) . The nucleotide triplets immediately adjacent to the sequence ladder were read directly from the gel. Flanking these triplets are the reverse complement nucleotides (i.e., the coding strand) and also the amino acid translation. The asterisk marks the site of change in the reverse strand. mutation in the 3' acceptor splice site of intron 6, preventing its removal. This mutation may lead to truncation after Trp-214 due to a stop codon at the 5' end of intron 6. Alternatively, ifthe 3' end ofexon 6 were spliced to the 5' end of exon 8, an exon-skipping event would result, eliminating exon 7 and causing a premature termination due to the frameshift. Thus, analbuminemia in humans may result from a variety of mutations and is genetically heterogeneous.
A different type of mutation occurs in the Nagase strain of analbuminemic rats; in this case the mutation occurs in an intron sequence and is a 7-bp deletion of nucleotides equivalent to 10, 888 in the human gene (26). This deletion results in the skipping of exon H, leading to a frameshift in exon I with a premature termination seven residues into exon 1 (27) . (Exons H and I in the rat gene are equivalent to exons 9 and 10, respectively, in the human gene.)
Putative Size of Aborted Albumin Product. Very small amounts of immunoreactive albumin have been reported for most cases of analbuminemia described in the literature. The question thus arises whether any intact albumin or albumin fragments are made by the subjects. Fig. 5 compares the size of normal mature HSA with the putative albumin fragments encoded by the mutated genes in five human cases of analbuminemia and also shows the putative albumin product in the case ofthe Nagase strain ofanalbuminemic rats (26, 27, 31) . The size ofthe truncated albumin that might be produced in the three cases described here and in the other two reported instances of human analbuminemia ranges from 31to 273-amino acid residues (Fig. 5 ), but no evidence for such products was obtained. In the case of the American Indian in vitro RNA splicing between exons 6 and 7 was shown to be aberrant; no evidence for a protein product was obtained (11). Studies of RNA splicing were not done in the other four cases of human analbuminemia. The mutant albumin gene in the Nagase rat could encode an albumin fragment of 336amino acid residues (26, 27) . Analysis of protein synthesis and transport within the hepatocytes ofNagase rats indicated that several sizes of albumin-like proteins accumulate within certain organelles but are not secreted in significant amounts (31). Because it is difficult to exclude leakiness ofthe gene or alternative (cryptic) splicing sites, the synthesis and secretion of minute amounts of albumin or albumin fragments by analbuminemics cannot be excluded. Analbuineia, Hyperipidemia, and Edema. Although its use is diminishing, i.v. administration of albumin has been widely used in clinical practice to restore and maintain colloid osmotic pressure in cirrhosis and nephrosis and also after surgery, shock, trauma, and burns (32). Indeed, --5 x 106 units of albumin are used annually for these purposes in the Proc. Nad. Acad. Sci. USA 91 (1994) 
